CFO departs Annovis Bio (ANVS) as CEO Maria Maccecchini takes acting finance role

Rhea-AI Filing Summary

Annovis Bio, Inc. reported that effective March 23, 2026, Chief Financial Officer Mark Guerin is no longer employed by the company. The company stated that his departure did not arise from any disagreement regarding operations, policies, or practices.

The board of directors is expected to appoint Chief Executive Officer Maria Maccecchini to serve as Acting Chief Financial Officer until a permanent replacement is identified, temporarily combining the CEO and CFO responsibilities.

Positive

• None.

Negative

• CFO departure and interim coverage by CEO: The Chief Financial Officer role is vacant as of March 23, 2026, with the CEO expected to serve as Acting CFO, reducing separation between executive leadership and financial oversight until a permanent replacement is named.

Insights

Corporate governance analyst

CFO exit creates leadership transition, with CEO stepping in temporarily.

Annovis Bio disclosed that CFO Mark Guerin is no longer employed as of March 23, 2026. The company explicitly notes there was no disagreement over operations, policies, or practices, which helps limit concern about internal disputes or accounting issues.

The board plans to have CEO Maria Maccecchini act as interim CFO. Concentrating both roles in one person can be manageable short term but reduces separation between strategic leadership and financial oversight. Investors often look for clarity on how long this dual role will last and the timetable for appointing a new CFO.

The key factor will be how quickly a qualified permanent CFO is hired and whether future disclosures describe any changes in financial reporting processes after March 23, 2026. Stability in the finance function can be important for budgeting, capital planning, and interactions with lenders or partners.

false 0001477845 0001477845 2026-03-23 2026-03-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 23, 2026

ANNOVIS BIO, INC.

(Exact Name of Registrant as Specified in Charter) 

Delaware	001-39202	26-2540421
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

101 Lindenwood Drive, Suite 225
Malvern, PA 19355

(Address of Principal Executive Offices, and Zip Code)

(484) 875-3192

Registrant’s Telephone Number, Including Area Code

                       Not Applicable                       

(Former Name or Former Address, if Changed Since Last Report) 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	ANVS	New York Stock Exchange

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Effective March 23, 2026, Mark Guerin is no longer employed as as Chief Financial Officer of Annovis Bio, Inc. (the “Company”). Mr. Guerin’s departure did not arise from any disagreement with the Company or any matter relating to the Company’s operations, policies or practices. The Company anticipates that the board of directors of the Company will appoint Maria Maccecchini, Chief Executive Officer of the Company, to serve as Acting Chief Financial Officer of the Company until a replacement can be identified.

Item 9.01 Financial Statements and Exhibits

Exhibit Number		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ANNOVIS BIO, INC.
Date: March 25, 2026	By:	/s/ Maria Maccecchini
		Name:	Maria Maccecchini
		Title:	President and Chief Executive Officer

FAQ

What leadership change did Annovis Bio (ANVS) disclose in this 8-K filing?

Annovis Bio reported that Chief Financial Officer Mark Guerin is no longer employed as of March 23, 2026. The company stated his departure did not result from any disagreement about operations, policies, or practices, framing it as a non-dispute-related transition.

Did Annovis Bio (ANVS) indicate any disagreements related to the CFO’s departure?

The company explicitly stated that Mr. Guerin’s departure did not arise from any disagreement with Annovis Bio. This language is important because it suggests no reported disputes over operations, policies, or practices that might raise concern about internal conflicts or reporting issues.

Who will handle CFO responsibilities at Annovis Bio (ANVS) after March 23, 2026?

Annovis Bio expects its board of directors to appoint CEO Maria Maccecchini as Acting Chief Financial Officer. She would temporarily assume both CEO and CFO roles, overseeing financial functions until the company identifies and appoints a permanent replacement for the CFO position.

Does the Annovis Bio (ANVS) filing specify when a new permanent CFO will be hired?

The filing notes the company will have CEO Maria Maccecchini serve as Acting Chief Financial Officer until a replacement can be identified. It does not provide a specific timeline, only indicating the intent to appoint a permanent CFO after a search and selection process.

What form did Annovis Bio (ANVS) use to report the CFO change?

Annovis Bio used a Form 8-K to report this leadership change under the Securities Exchange Act of 1934. This form is typically used to disclose significant corporate events, such as executive departures or appointments, that may be important to shareholders and the broader market.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.8 KB